CRISPR and infectious diseases: Potential and challenges.

Kun He*

Department of Global Health, Shanghai University, China

Introduction

The CRISPR-Cas9 system works by utilizing an RNA molecule to guide the Cas9 enzyme to a specific sequence in the DNA. Once there, Cas9 acts like molecular scissors, making cuts at precise locations. This ability to edit genes with such precision opens up numerous possibilities in the realm of infectious diseases. For instance, CRISPR can be used to directly target the genetic material of pathogens. By designing CRISPR molecules to recognize and cut viral DNA or RNA, scientists can potentially disable viruses such as HIV, hepatitis B, and herpes simplex virus. This approach could lead to treatments that are more effective than current antiviral therapies, which often struggle with issues like drug resistance and incomplete viral suppression [1, 2].

Beyond directly targeting pathogens, CRISPR can also be employed to enhance the human immune system's ability to fight infections. By editing the genes of immune cells, researchers can create cells that are better equipped to recognize and attack pathogens. This strategy is being explored in the context of HIV, where scientists are attempting to create immune cells that are resistant to the virus by removing the CCR5 receptor, a protein that HIV uses to enter cells. Such genetic modifications could potentially lead to a functional cure for HIV, allowing patients to control the virus without the need for ongoing antiretroviral therapy [3, 4].

Another exciting application of CRISPR is in the development of diagnostic tools. Traditional diagnostic methods for infectious diseases can be time-consuming and often lack sensitivity. CRISPR-based diagnostics, however, can detect the presence of pathogens with high accuracy and speed. For example, the SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) and DETECTR (DNA Endonuclease-Targeted CRISPR Trans Reporter) systems use CRISPR to identify viral RNA or DNA in patient samples, providing rapid and accurate diagnosis. This capability is particularly valuable in outbreak situations, where early and accurate detection is crucial for controlling the spread of disease [5, 6].

Despite the immense potential of CRISPR in addressing infectious diseases, there are significant challenges that need to be addressed. One major concern is the potential for off-target effects. While CRISPR is highly precise, it is not infallible. Unintended edits to the genome can occur, potentially leading to harmful consequences such as the activation of oncogenes or disruption of essential genes. Therefore, improving the specificity of CRISPR and developing robust methods for detecting and minimizing off-target effects is crucial for its safe application in humans [7, 8].

Ethical and regulatory considerations also play a significant role in the development and deployment of CRISPR technologies. The ability to edit human genes raises profound ethical questions, particularly concerning the potential for germline editing, where changes to the DNA can be passed on to future generations. While germline editing holds the potential to eradicate certain genetic diseases, it also carries significant risks and ethical concerns. The scientific community and regulatory bodies must navigate these complex issues to ensure that CRISPR is used responsibly and ethically [9, 10].

Conclusion

CRISPR technology represents a revolutionary tool in the fight against infectious diseases. Its ability to precisely edit genetic material offers unprecedented opportunities for developing new treatments, enhancing immune responses, and creating rapid diagnostic tools. However, to fully harness the potential of CRISPR, it is essential to address the technical challenges, ethical considerations, and issues of accessibility and public perception. By doing so, we can pave the way for CRISPR to become a cornerstone of modern medicine, offering new hope in the battle against infectious diseases.

References

1. Hussein M, Molina MA, Berkhout B, et al. A CRISPR-Cas Cure for HIV/AIDS.Int J Mol Sci. 2023;24(2):1563.
2. Bhowmik R, Chaubey B. CRISPR/Cas9: a tool to eradicate HIV-1. AIDS Res Ther. 2022;19(1):58.
3. Fozouni P, Son S, de León Derby MD, et al. Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy. Cell. 2021;184(2):323-33.
4. Pandey M, Ojha D, Bansal S, et al. From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases. Mol Aspects Med. 2021;81:101003.
5. Nidhi S, Anand U, Oleksak P, et al. Novel CRISPR–Cas systems: an updated review of the current achievements, applications, and future research perspectives. Int J Mol Sci. 2021;22(7):3327.

***Correspondence to:** Kun He**,** Department of Global Health, Shanghai University, China. E-mail: kunhey3@tu.edu.cn

***Received:** 26-Feb-2024, Manuscript No. AAJIDMM-24-142969; **Editor assigned:** 28- Feb -2024, PreQC No. AAJIDMM-24-142969 (PQ); **Reviewed:** 13-Mar-2024, QC No. AAJIDMM-24-142969; **Revised:** 15- Mar-2024, Manuscript No. AAJIDMM-24-142969 (R); **Published:** 20- Mar-2024, DOI:10.35841/aajidmm-8.2.195*

***Citation:** He K. CRISPR and infectious diseases: Potential and challenges. J Infect Dis Med Microbiol. 2024;8(2):195.*

6. Qu J, Kalyani FS, Liu L, et al. Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy.Cancer Commun (Lond). 2021;41(12):1331-53.
7. Gleerup JL, Mogensen TH. CRISPR-Cas in diagnostics and therapy of infectious diseases. J Infect Dis. 2022;226(11):1867-76.
8. Dubey AK, Mostafavi E. Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy. Front Chem. 2023;11.
9. Binnie A, Fernandes E, Almeida-Lousada H, et al. CRISPR-based strategies in infectious disease diagnosis and therapy. Infection. 2021;49:377-85.
10. Grosch M, Schraft L, Chan A, et al. Striated muscle-specific base editing enables correction of mutations causing dilated cardiomyopathy. Nat Commun. 2023;14(1):3714.

Citation: *He K. CRISPR and infectious diseases: Potential and challenges. J Infect Dis Med Microbiol. 2024;8(2):195.*